|
We celebrated our fifth anniversary this spring. The last few years have been characterised by continuous growth, professionalisation and forward-looking innovations. So, we have quickly grown into a young company established in the biotech sector.
In the last couple of years we have reached several milestones such as setting up our own biochip production, development of organ-on-chip infection models, significant improvement in strategic topics in the area of sales, company growth and team development or future driven cooperations with reasearch groups and several companies.
Now, we are looking forward to another eventful year in which we will be able to announce some great cooperation projects and more of our own developments.
We continue to see far-reaching potential in the idea that animal testing can be reduced or even partly replaced in basic research and pharmaceutical development according to the 3Rs principle (Replace, Reduce, Refine).
The market for organ-on-chip systems, which is becoming increasingly relevant, and with Dynamic42 as part of it, cannot only enable safer testing of pharmaceuticals and substances in the future, but it can also further help to generate new insights into disease processes, therapy options and associated mode of actions as well as approaches to individualised medicine.
|
